ImmucorGamma to Be Acquired by Private Investment Firm for US$1.973 Billion

ImmucorGamma, Inc. (Immucor; Norcross, GA, USA), a leading global in vitro diagnostics company specializing in pretransfusion automated instrumentation, announced that it has signed a definitive agreement to be acquired by the international private equity firm TPG Capital (Fort Worth, TX, USA) for US$1.973 billion. The transaction is expected to finalize in the second half of 2011.

"This transaction enables our shareholders to realize significant, immediate value while at the same time allowing Immucor to remain well positioned to continue pursuing growth opportunities," said Joseph Rosen, chairman of the board of directors of Immucor. "Partnering with TPG will allow us to continue with our commitment to deliver innovative technologies that meet our customers' needs and improve patient safety," Joshua H. Levine, president and CEO of Immucor said.

"By offering best-in-class instruments and reagents for the blood transfusion industry, Immucor has built an impressive platform, loyal customer base, and a strong leadership position," said Todd Sisitsky, TPG Partner. "We look forward to working with the Immucor team as we invest in growing the business and expanding the global footprint for these vital services."

Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of its market segments.

TPG Capital is a leading global private investment firm founded in 1992 with $48 billion of assets under management and offices in San Francisco, Beijing, Fort Worth, Hong Kong, London, Luxembourg, Melbourne, Moscow, Mumbai, New York, Paris, Shanghai, Singapore, and Tokyo. TPG Capital has extensive experience with global public and private investments executed through leveraged buyouts, recapitalizations, spinouts, growth investments, joint ventures, and restructurings. TPG Capital's healthcare investments have included Aptalis Pharma, Biomet, Fenwal, Healthscope, IASIS Healthcare, IMS Health, Oxford Health Plans, Parkway Holdings, Quintiles Transnational, Surgical Care Affiliates, among others.

Related Links:
ImmucorGamma
TPG Capital